Dr. Josep Tabernero Caturla is a medical oncologist associated with Vall d’Hebron University Hospital and the Vall d’Hebron Institute of Oncology in Barcelona, Spain. He is recognized for his work in gastrointestinal oncology, molecular cancer research, and the development of personalized approaches to cancer treatment.

His professional responsibilities include leadership of the Medical Oncology Department at Vall d’Hebron, direction of VHIO, and coordination of research into molecular cancer therapies. His work connects clinical oncology with translational research, helping investigate how tumor biology and molecular characteristics can inform treatment decisions.

Specialization in Gastrointestinal Oncology

Dr. Tabernero’s clinical and research interests include gastrointestinal malignancies such as colorectal cancer, gastroesophageal cancer, pancreatic cancer, and liver tumors. These conditions can require complex diagnostic assessments and coordinated treatment involving medical oncologists, surgeons, radiologists, pathologists, and other specialists.

The treatment approach for gastrointestinal cancers depends on the tumor's location, stage, molecular profile, previous treatments, and the patient's overall health. Treatment options may include chemotherapy, targeted medicines, immunotherapy in appropriate cases, surgery, and participation in clinical trials.

Precision Oncology and Molecular Therapies

An important part of Dr. Tabernero’s work involves precision oncology. This approach uses information about a tumor’s molecular characteristics to help identify treatment options that may be appropriate for an individual patient.

His research has included pharmacodynamic studies, translational projects, targeted therapies, and immune-based cancer treatments. The Cancer Molecular Therapy Research Unit at Vall d’Hebron has been involved in early-phase clinical trials investigating new approaches to cancer treatment.

Vall d'Hebron Barcelona Hospital

+1

For international patients, molecular testing and specialist review can help clarify which treatment approaches are available and whether a clinical trial may be suitable. Eligibility depends on specific medical criteria and trial availability.

Academic and Research Contributions

Dr. Tabernero completed his medical studies at the Universitat Autònoma de Barcelona in 1987 and subsequently earned his doctorate. He has held academic and research responsibilities and has been involved in international oncology organizations, including the European Society for Medical Oncology and the American Society of Clinical Oncology.

His professional work includes scientific publications, participation in clinical research, and contributions to oncology education. These activities support the integration of scientific evidence into specialist cancer care.

International Patient Information

Patients considering treatment in Barcelona can prepare recent pathology reports, biopsy results, molecular testing, imaging studies, and previous treatment records for specialist evaluation. These documents help the treating team assess the diagnosis and discuss possible treatment pathways.

A consultation does not guarantee eligibility for a specific therapy or clinical trial. Treatment recommendations should follow a complete medical assessment and multidisciplinary review where appropriate.